New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 28, 2014
09:36 EDTAAPL, TWTR, TSLA, QCOR, C, FB, GOOG, AMZNActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL C TSLA QCOR MNKD GOOG NFLX AMZN FB TWTR
News For AAPL;TWTR;TSLA;QCOR;C;FB;GOOG;AMZN From The Last 14 Days
Check below for free stories on AAPL;TWTR;TSLA;QCOR;C;FB;GOOG;AMZN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>
July 15, 2014
10:33 EDTTWTR, FBFacebook, Twitter slip following cautious valuation comments from Fed
Shares of a number of companies in the social media and biotech industries moved lower following the circulation of cautious comments about their stock valuations that were included in the Federal Reserve's latest Monetary Policy Report. WHAT'S NEW: In the report, presented by the Board of Governors of the Federal Reserve and signed on behalf of the governors by Chair Janet Yellen, the central bank wrote that some broad equity price indexes have increased to all-time highs in nominal terms since the end of 2013, but that valuation measures for the overall market in early July were "generally at levels not far above their historical averages." However, the Fed's report also cautioned that valuation metrics in some sectors do appear substantially "stretched," particularly those for smaller firms in the social media and biotechnology industries, despite a notable downturn in equity prices for such firms early in the year. As support for its assessment, the Fed noted that ratios of prices to forward earnings for "smaller firms as well as social media and biotechnology firms" remain "high relative to historical norms." PRICE ACTION: Following the circulation of the comments in the Fed report, shares of Facebook (FB) are down 88c, or 1.3%, to $67.02, Twitter (TWTR) is down 24c, or 0.6%, to $38.07 and LinkedIn (LNKD), is down 21c, or 0.1%, to $159.57. Shares of some biotechnology companies including Celgene (CELG) and Amgen (AMGN) also ticked lower following the circulation of the comments from the Fed's report.
10:18 EDTFB, TWTRFacebook, Twitter move lower following comments from Yellen
Subscribe for More Information
10:00 EDTGOOGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTTWTROn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:40 EDTAAPLApple 'iWatch' said to debut in two sizes, three models, AppleInsider says
Subscribe for More Information
09:38 EDTFB, AAPL, TSLAActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL FB JPM TSLA
09:05 EDTAMZNSanDisk to benefit from Amazon use of flash storage, says Pacific Crest
Subscribe for More Information
08:18 EDTTWTRTwitter cracks down on providers of user stats, BI says
After Twitter's stock declined early this year following data that suggested growth in its monthly active users was slowing or flat and that engagement measures were declining, the social network operator has taken the unusual step of shutting off its data flow to certain companies that have published their own stats on Twitter's user statistics, according Business Insider, citing two sources. Reference Link
07:43 EDTCCitigroup successfully executing plan, says RBC Capital
Subscribe for More Information
07:37 EDTCAmerican Enterprise Institute holds a discussion
Subscribe for More Information
07:34 EDTCCitigroup shares cheap on valuation, says UBS
UBS views Citigroup shares as cheap and does not expect them to trade below tangible book value indefinitely. The firm sees earnings stabilization, better than expected trading results, strong loan growth, and valuation as reasons to maintain its Buy rating and raise its price target on Citigroup shares to $61 from $60.
07:23 EDTFB, AMZNFortune to hold a conference
Subscribe for More Information
07:15 EDTGOOGIIR Holdings to hold a conference
14th Annual Shopper Insights in Action Conference to be held in Chicago on July 14-16.
06:43 EDTAAPLApple reportedly considering Carney for PR head position, Re/code reports
Subscribe for More Information
06:20 EDTAAPLBoy's rash linked to possible exposure to nickel found in iPad, WSJ reports
Subscribe for More Information
06:15 EDTGOOGGoogle Fit may benefit remote medical care industry, DigiTimes Research says
Subscribe for More Information
06:13 EDTFBFacebook, Nielsen team up to track TV habits, LA Times reports
Subscribe for More Information
06:06 EDTTWTRTwitter upgraded to Neutral from Underperform at Macquarie
Macquarie upgraded its rating on Twitter (TWTR) to Neutral saying a reset in expectations and improving fundamentals will limit downside in the stock. The firm believes user growth trends remain an issue, though, and remains cautious on the name. Macquarie has a $36 price target for Twitter shares, which closed yesterday down 2c to $38.31.
06:02 EDTGOOGSamsung, Nest, ARM team up for Thread wireless networking protocol
Subscribe for More Information
05:44 EDTGOOGNovartis to license Google 'smart lens' technology
Novartis (NVS) announced that its eye care division Alcon has entered into an agreement with a division of Google (GOOG) to in-license its "smart lens" technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google's "smart lens" technology with the potential to transform eye care and further enhance Alcon's pipeline and global leadership in contact lenses and intraocular lenses. The transaction remains subject to anti-trust approvals. The agreement between Google and Alcon represents an important step for Novartis, across all of its divisions, to leverage technology to manage human diseases and conditions. Google's key advances in the miniaturization of electronics complement Novartis's deep pharmaceuticals and medical device expertise. Novartis aims to enhance the ways in which diseases are mapped within the body and ultimately prevented.
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use